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Abstract
Objectives. Vaccines that prime Wilms’ tumor 1 (WT1)-specific
CD8+ T cells are attractive cancer immunotherapies. However,
immunogenicity and clinical response rates may be enhanced by
delivering WT1 to CD141+ dendritic cells (DCs). The C-type lectin-
like receptor CLEC9A is expressed exclusively by CD141+ DCs and
regulates CD8+ T-cell responses. We developed a new vaccine
comprising a human anti-CLEC9A antibody fused to WT1 and
investigated its capacity to target human CD141+ DCs and activate
na€ıve and memory WT1-specific CD8+ T cells. Methods. WT1 was
genetically fused to antibodies specific for human CLEC9A, DEC-
205 or b-galactosidase (untargeted control). Activation of WT1-
specific CD8+ T-cell lines following cross-presentation by CD141+
DCs was quantified by IFNc ELISPOT. Humanised mice
reconstituted with human immune cell subsets, including a
repertoire of na€ıve WT1-specific CD8+ T cells, were used to
investigate na€ıve WT1-specific CD8+ T-cell priming. Results. The
CLEC9A-WT1 vaccine promoted cross-presentation of WT1 epitopes
to CD8+ T cells and mediated priming of na€ıve CD8+ T cells more
effectively than the DEC-205-WT1 and untargeted control-WT1
vaccines. Conclusions. Delivery of WT1 to CD141+ DCs via CLEC9A
stimulates CD8+ T cells more potently than either untargeted
delivery or widespread delivery to all Ag-presenting cells via DEC-
205, suggesting that cross-presentation by CD141+ DCs is sufficient
for effective CD8+ T-cell priming in humans. The CLEC9A-WT1
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vaccine is a promising candidate immunotherapy for malignancies
that express WT1.
Keywords: cancer immunotherapy, CD141, CLEC9A, dendritic cells,
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INTRODUCTION
Relapse after initial treatment is a major problem
in the clinical management of acute myeloid
leukaemia (AML). Moreover, there are no
effective treatments for myelodysplastic syndrome
(MDS), which predisposes to AML. In these and
other haematological malignancies, vaccines that
prime and/or boost tumor-specific CD8+ T cells are
attractive therapeutic options to prevent or delay
disease progression, especially in the setting of
minimal residual disease (MRD).1,2 As the initiators
and orchestrators of adaptive immunity, dendritic
cells (DCs) are essential for the induction of
tumor-specific CD8+ T-cell responses.3,4 DC-based
vaccines have been administered safely to
thousands of cancer patients over the past two
decades, with clear evidence of immunogenicity
and some indications of clinical efficacy, most
notably in patients with AML.2 Clinical response
rates may nonetheless be improved by more
potent vaccines.1,5
The transcription factor Wilms’ tumor 1 (WT1) is
one of the best characterised and most highly
immunogenic tumor-associated antigens (TAAs)
and is an excellent target for therapeutic cancer
vaccines.6 WT1 is overexpressed in a range of
haematological and solid malignancies, including
most cases of AML.7 Indeed, peripheral blood
measurements of WT1 mRNA are routinely used
to detect and monitor MRD in patients with AML
or MDS.8 WT1 is minimally expressed in somatic
tissues, but it is expressed by leukaemic stem cells
and plays an important role in leukaemogenesis,
making it less prone to immune escape. WT1 is
also highly immunogenic and contains epitopes
restricted by multiple HLA allotypes that are
recognised by CD4+ or CD8+ T cells.7,9 Although
peptide-based vaccines can elicit functional WT1-
specific CD8+ T-cell responses and show
therapeutic efficacy in some patients,10,11 they
largely fail to elicit long-term memory responses
that incorporate high-avidity WT1-specific CD8+ T
cells.12,13 A more promising approach has been
the development of cell-based vaccines comprising
autologous monocyte-derived DCs (moDCs) loaded
in vitro with WT1 mRNA, which have been shown
to prevent and/or delay relapse after
chemotherapy and improve overall survival in
patients with high-risk AML.14,15 However, moDC-
based vaccines are expensive, labour-intensive,
and require specialist facilities, and greater
immunogenicity may be achieved by targeting
other subsets of DCs.2,3,5 An unmet clinical need
therefore exists for improved ‘off-the-shelf’
vaccine formulations that elicit potent immune
responses against WT1.
Antibodies (Abs) specific for antigen (Ag)
uptake receptors are attractive candidates for the
delivery of vaccine cargo directly to DCs
in vivo.3,16 For example, Abs specific for the C-
type lectin receptor DEC-205 can deliver TAAs to
DCs, which prime TAA-specific CD4+ and CD8+
T-cell responses and display greater therapeutic
efficacy in mice than other vaccine
formulations.17-19 Moreover, vaccination with a
human DEC-205-specific Ab conjugated to NY-
ESO-1 and combined with the adjuvant polyICLC
was feasible and well tolerated in patients with
advanced solid malignancies and MDS, and in
some cases, enhanced NY-ESO-1-specific CD4+ and
CD8+ T-cell responses were observed after
vaccination.20,21 In addition, DEC-205-specific Ab-
based vaccines can be combined with standard
treatments, including doxorubicin and/or
decitabine,21,22 and may benefit patients receiving
checkpoint inhibitors.20
Dendritic cells comprise several distinct subsets
with highly specialised roles in the generation of
specific immune responses.4 In humans, DEC-205 is
widely expressed by most leucocytes, including all
DCs.23 Vaccine immunogenicity may therefore be
enhanced by specifically targeting particular
subtypes of DCs. In mice, CD8+ T-cell-mediated
control of various tumors relies on the activity of
conventional type 1 dendritic cells (cDC1s), which
have also been identified as Batf3-dependent,
CD103+ tissue-resident, and CD8a+ lymphoid-
resident DCs.24-27 Moreover, cDC1s underpin the
efficacy of various cancer therapies, including
adoptive T-cell transfer,28,29 radiotherapy,
immunogenic and oncolytic virus-based
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interventions,30,31 agonistic anti-CD137 Abs,32 and
immune checkpoint inhibitors.32,33 The human
cDC1 equivalents are known as CD141+ DCs.34-37
They are more effective than moDCs at cross-
presenting cellular Ags, a key process in the
generation of tumor-specific CD8+ T-cell
responses.34,38 Moreover, the presence of CD141+
DCs in many human solid tumors correlates
positively with prolonged survival and enhanced
responses to anti-PD-1 therapy.28,29,39,40
The C-type lectin-like receptor CLEC9A, also
called DNGR-1, is an attractive target for vaccine
enhancement, because it is exclusively expressed
by CD141+ DCs and plays a critical role in the
recognition and cross-presentation of necrotic
cells Ags.41-45 Anti-mouse CLEC9A Abs are as
effective as anti-mouse DEC-205 Abs at delivering
Ags to murine cDC1s in vivo to prime CD8+ T-cell
responses,46 as well as humoral and CD4+ T-cell
responses, which collectively mediate protective
tumor-specific immunity.41,42 We previously
developed vaccines comprising anti-human
CLEC9A or anti-human DEC-205 IgG4 Abs
genetically fused to a long peptide (40 amino
acids) from the human cytomegalovirus (CMV)
pp65 Ag.47 Despite similar uptake and
internalisation of these anti-CLEC9A and anti-DEC-
205 Abs by CD141+ DCs, and a comparable ability
to stimulate CMV-specific memory CD4+ T-cell
responses, the anti-CLEC9A Ab more effectively
targeted the cross-presentation pathway in
CD141+ DCs, leading to greater activation of
pp65-specific memory CD8+ T cells in HLA class I
transgenic NOD/SCID/IL2rgKO (NSG) mice.
However, it is unclear if similarly beneficial effects
could be elicited in humans by exclusively
targeting TAA to the rare CD141+ DC subset via
CLEC9A.
In this study, we developed chimeric vaccines
comprising anti-human CLEC9A or anti-human
DEC-205 IgG4 Abs genetically fused to a
polypeptide from WT1. The CLEC9A-WT1 vaccine
more effectively promoted cross-presentation of
HLA-A*0201-restricted and HLA-A*2402-restricted
WT1 epitopes by CD141+ DCs, leading to greater
activation of WT1-specific CD8+ T cells. Using a
novel humanised mouse model in which human
DC subsets develop in vivo, we also found that
the CLEC9A-WT1 vaccine effectively primed na€ıve
CD8+ T cells. Collectively, these data identify a
promising new vaccine candidate for malignancies
that express WT1.
RESULTS
Generation and validation of human
CLEC9A-WT1 and DEC-205-WT1 vaccines
We previously developed constructs encoding
human chimeric IgG4 Abs specific for CLEC9A,
DEC-205, and b-gal (untargeted isotype control).47
The WT1 sequence, encoding both the HLA-
A*2402-restricted WT1235–243 epitope and the
HLA-A*0201-restricted WT1126–134 epitope, was
genetically fused to the heavy chain of each Ab
via an alanine linker, so that each Ab contained
two WT1 antigenic sequences (Figure 1a). After
expression in 293F cells and purification by
affinity chromatography, Ab binding specificity to
target receptors was confirmed on CLEC9A-
transfected or DEC-205-transfected cell lines by
ELISA and further evaluated on PBMCs by flow
cytometry (Figure 1b and Supplementary figure
1). As expected, CLEC9A-WT1 bound specifically to
CD141+ DCs, whereas DEC-205-WT1 bound to
most human leucocyte subsets, with the highest
staining intensity observed on CD1c+ DCs and
CD141+ DCs (Figure 1b).
Cross-presentation of WT1 epitopes by
CD141+ DCs after uptake of CLEC9A-WT1
As CD141+ DCs are extremely rare in human
blood, we derived these cells from human cord
blood CD34+ HSCs, either in vitro (Supplementary
figure 2) using a previously validated culture
system48 or in vivo using a humanised mouse
model.49-51 The functional, phenotypic, and
transcriptomic properties of the CD141+ DCs that
emerge in each system closely resemble those of
their naturally occurring counterparts.48-51 The
CLEC9A-WT1 and DEC-205-WT1, but not the
control-WT1 vaccine, bound to in vitro-derived
CD141+ DCs. Of note, DEC-205-WT1 stained with
greater intensity than CLEC9A-WT1 in all donors,
although this trend did not reach statistical
significance (Figure 2a and b). The CLEC9A-WT1
vaccine also facilitated cross-presentation of the
HLA-A*2402-restricted WT1235–243 epitope by
purified CD141+ DCs to WT1235–243-specific CD8
+ T
cells (Figure 2c, Supplementary figure 3). Similarly,
efficient cross-presentation of the HLA-A*0201-
restricted WT1126–134 epitope to specific CD8
+ T
cells was observed after incubation of HLA-
A*0201+ CD141+ DCs with the CLEC9A-WT1
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vaccine (Figure 2d). In contrast, the DEC-205-WT1
and control-WT1 vaccines were ineffective at
delivering WT1 to CD141+ DCs for cross-
presentation of either the WT1126–134 epitope or
the WT1235–243 epitope (Figure 2c and d).
DCs and na€ıve WT1-specific CD8+ T cells
develop in humanised mice
To investigate the in vivo effects of CLEC9A-WT1
and DEC-205-WT1 vaccines, we generated
humanised mice reconstituted with human
immune cell subsets, including a small repertoire
of na€ıve WT1235–243-specific CD8
+ T cells (Figure 3).
Initially, HLA-A*2402+ human HSCs were
transduced with a lentivirus expressing a
prearranged WT1235–243-specific TCR and the
reporter gene rat CD2. These transduced HSCs
were then administered to immunodeficient NSG-
A24 neonatal mice (Figure 3a). After 10–14 weeks,
human T cells, B cells, monocytes, and DC subsets
were reconstituted in the spleens of humanised
mice at frequencies similar to those reported
previously49,52 (Figure 3b and c). The functional,
phenotypic, and transcriptomic properties of
human DC subsets generated in humanised mice
closely resemble those of their human peripheral
blood counterparts.49-51 Moreover, transduction of
the TCR transgene into human CD34+ HSCs before
the development of CD8+ T cells in vivo enables
thymic selection of human HLA-A*2402+ CD8+ T
cells in NSG-A24 mice. Introduction of the TCR
transgene also inhibits endogenous TCR gene
rearrangement, resulting in exclusive expression
of the transgenic TCR on the cell surface via a
process known as allelic exclusion.53 An average
of 13.17% ! 26.34% of engrafted human CD8+ T
cells in the peripheral blood expressed rat CD2,
Figure 1. Generation and validation of human CLEC9A-WT1 and DEC-205-WT1 vaccines. (a) Diagram of a chimeric Ab comprising rat or mouse
variable regions specific for human CLEC9A, human DEC-205, or bacterial b-galactosidase (b-gal), and human IgG4 and j constant regions
genetically fused to an antigenic sequence from WT1 containing the HLA-A*201-restricted WT1126–134 (RMFPNAPYL) and HLA-A*2402-restricted
WT1235–243 (CMTWNQMNL) epitopes, a pan-MHC II epitope (KLSHLQMHSRKH), and a FLAG tag. (b) Flow cytometric analysis of CLEC9A-WT1
(white, left panels), DEC-205-WT1 (white, right panels) and control-WT1 (grey, control) binding to human PBMCs. Data are representative of
three healthy blood donors.
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indicative of successful integration of the
transgene, but only a small proportion (< 2%)
expressed detectable cell surface levels of the
WT1235–243-specific TCR (Figure 3d). All of the
transduced CD8+ T cells in these humanised mice
coexpressed CD45RA and CCR7, consistent with a
na€ıve phenotype (Figure 3e). The expressed
WT1235–243-specific TCR also transduced a
functional signal, leading to the production of
IFNc after stimulation of humanised mouse
splenocytes with the cognate WT1235–243 peptide
(Figure 3f).
Figure 2. Cross-presentation of WT1 epitopes by CD141+ DCs after uptake of CLEC9A-WT1. (a, b) Binding of CLEC9A-WT1, DEC-205-WT1 and
b-gal-WT1 (control) Abs to in vitro differentiated CD141+ DCs. (a) Histograms from one representative donor. (b) Median fluorescence intensity
(MFI) mean + SD from four donors. (c) Cross-presentation of the WT1235–243 epitope to WT1235–243-specific CD8
+ T cells by HLA-A*2402+
CD141+ DCs cultured with CLEC9A-WT1, DEC-205-WT1 or b-gal-WT1 (control). Data are shown as mean + SD (five donors). CTL, cytotoxic T
lymphocyte; SFU, spot-forming unit (IFNc ELISPOT assay). *P = 0.0173, **P = 0.0014 (one-way ANOVA with Tukey’s test for multiple
comparisons). (d) Cross-presentation of the WT1126–134 epitope to WT1126–134-specific CD8
+ T cells by HLA-A*0201+ CD141+ DCs cultured with
CLEC9A-WT1, DEC-205-WT1 or b-gal-WT1 (control). Data shown are mean + SD (pooled replicates from three donors). CTL, cytotoxic T
lymphocyte; SFU, spot-forming unit (IFNc ELISPOT assay). *P < 0.0001 (one-way ANOVA with Tukey’s test for multiple comparisons).
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Figure 3. DCs and na€ıve WT1-specific CD8+ T cells develop in humanised mice. (a) Diagram showing the generation of humanised NSG-A24
mice using cord blood-derived HSCs transduced with a lentivirus expressing a WT1235–243-specific TCR. (b, c) Human CD45
+ cell reconstitution in
spleens from humanised NSG-A24 mice. (b) Representative dot plots. (c) Human CD45+ cell subset composition (Means ! SD from three mice).
(d) Expression of the WT1235–243-specific TCR on splenic human na€ıve CD3
+ CD8+ T cells, detected using the corresponding tetramer and rat
CD2. (e) Phenotype of CD3+ CD8+ T cells, gated on total transduced cells (rCD2+, top) or transduced cells expressing the WT1235–243-specific TCR
(bottom). CM, central memory (CD45RA" CCR7+); EM, effector memory (CD45RA" CCR7"); EMRA, terminally differentiated effector memory
(CD45RA+ CCR7"); N, na€ıve (CD45RA+ CCR7+). (f) IFNc production after incubation of humanised mouse splenocytes with WT1235–243 peptide
(ELISPOT assay). Data represent pooled replicates from five humanised mice.
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CLEC9A-WT1 induces priming of human
na€ıve WT1-specific CD8+ T cells
The capacity of DEC-205-WT1 to bind other DC
and leucocyte subsets (Figure 1b) raises the
possibility that inefficient cross-presentation by
monocytes, plasmacytoid DCs (pDCs) and CD1c+
DCs as well as CD141+ DCs could be as effective at
priming CD8+ T cells en masse as highly efficient
cross-presentation by only CD141+ DCs targeted
with CLEC9A-WT1. To address this question, we
first confirmed binding of CLEC9A-WT1, DEC-205-
WT1 and control-WT1 vaccines to human immune
cell populations that developed in the spleens of
humanised mice (as defined in Figure 3b and c).
As expected, CLEC9A-WT1 bound specifically to
CD141+ DCs (Figure 4a), which constituted only
2% of the total engrafted human CD45+
population (Figure 4b). DEC-205-WT1 also bound
to CD141+ DCs and, to a lesser extent, to CD1c+
DCs, B cells and monocytes, which together
represented more than 50% of the human CD45+
cell population (Figure 4a and b). Despite largely
equivalent binding of CLEC9A-WT1 and DEC-205-
WT1 to humanised mouse CD141+ DCs and a small
amount of non-specific binding of control-WT1 to
humanised mouse CD141+ DCs (Figure 4a), cross-
presentation of the WT1235–243 epitope by purified
humanised mouse CD141+ DCs to WT1235–243-
specific CD8+ T cells was only detectable after
incubation with CLEC9A-WT1 (Figure 4c). This
finding confirmed and extended our observations
with in vitro cultured CD141+ DCs (Figure 2c).
To determine whether human na€ıve CD8+ T cells
could be primed by specific targeting of CD141+
DCs via CLEC9A and/or broad targeting of more
abundant Ag-presenting cells via DEC-205, we
incubated bulk human CD45+ leucocytes from the
spleens of humanised mice containing na€ıve
WT1235–243-specific CD8
+ T cells (Figure 3a–f) with
CLEC9A-WT1, DEC-205-WT1 and control-WT1
vaccines and monitored the activation of CD8+ T
cells using an IFNc ELISPOT assay (Figure 4d). In
this model, only the CLEC9A-WT1 vaccine
effectively stimulated IFNc production (Figure 4d).
We also examined whether CLEC9A-WT1 could
induce the expansion of na€ıve WT1235–243-specific
CD8+ T cells (Figure 4e). In three of four donors,
CLEC9A-WT1 induced the expansion of rat CD2+
WT1235–243-specific TCR
+ CD8+ T cells over a period
of 8 days in culture to a similar or greater extent
than stimulation with the cognate peptide
(Figure 4e and Supplementary figure 4). In
contrast, DEC-205-WT1 and control-WT1 vaccines
failed to induce the expansion of WT1235–243-
specific CD8+ T cells, with the exception of one
donor population incubated with the control-WT1
vaccine (Figure 4e). Collectively, these data show
that specific delivery of Ag to CD141+ DCs via
CLEC9A stimulates CD8+ T cells more potently
than either untargeted delivery or widespread
delivery to all Ag-presenting cells via DEC-205.
DISCUSSION
In this study, we report the development of a
human CLEC9A-WT1 vaccine that specifically
delivers WT1 to CD141+ DCs, which efficiently
cross-present HLA-A*0201-restricted and HLA-
A*2402-restricted epitopes derived from WT1. We
found that targeting CD141+ DCs with CLEC9A-
WT1 resulted in more effective cross-presentation
of these WT1 epitopes compared with either an
untargeted control-WT1 vaccine or an equivalent
DEC-205-WT1 vaccine, which bound efficiently to
CD141+ DCs and more abundant subtypes of DCs.
Moreover, we showed that the CLEC9A-WT1
vaccine primed na€ıve WT1-specific CD8+ T cells
more effectively than the control-WT1 or DEC-
205-WT1 vaccines. These data identify CLEC9A-
WT1 as a promising new vaccine candidate for
malignancies that express WT1.
Our CLEC9A-WT1 vaccine offers several key
advantages over existing cancer vaccines that have
already shown promise in early clinical trials. First,
it can be produced as an ‘off-the-shelf’ clinical-
grade formulation, which circumvents the financial
and logistical issues associated with in vitro-
manufactured patient-specific vaccines. Second,
this prototype vaccine targets very precisely the key
DC subset required for the initiation of tumor-
specific immune responses, thereby maximising
potential efficacy while minimising off-target
effects.3,16 Moreover, the human IgG4 j backbone
contains two point mutations (S229P and L236E)
that enhance stability and minimise elimination via
Ab-dependent cellular cytotoxicity (ADCC) or
complement-dependent cytotoxicity (CDC), making
it suitable as a therapeutic agent.47 Of note, the
two United States Food and Drug Administration
(FDA)-approved anti-PD-1 checkpoint inhibitor Abs,
pembrolizumab and nivolumab, are similarly
structured IgG4 Abs. The human IgG4 isotype,
combined with the specificity of CLEC9A-WT1 for
CD141+ DCs, therefore favors retention in the
bloodstream, enhancing the longevity of exposure
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and the potential for T-cell activation. Third,
CLEC9A trafficks Ags to early endosomal
compartments, where cross-presentation is most
efficient.54 This critical function likely explains the
greater efficacy of CLEC9A-WT1 compared with
DEC-205-WT1. Fourth, our chimeric Ab vaccine
delivers WT1, which is currently recognised as one
of the most immunogenic TAAs. WT1 is widely
expressed by many human cancers and contains
numerous CD4+ and CD8+ T-cell epitopes
distributed across multiple HLA allotypes.6 It is also
expressed by cancer stem cells and plays a key role
Figure 4. CLEC9A-WT1 induces priming of human na€ıve WT1-specific CD8+ T cells. (a, b) Binding of CLEC9A-WT1, DEC-205-WT1 and b-gal-
WT1 (control) to humanised mouse splenocytes. (a) Median fluorescence intensity (MFI) across human immune cell subsets. (b) Per cent
frequency among total human CD45+ cells. Data are shown as mean + SD (three humanised mice). (c) Cross-presentation of the WT1235–243
epitope to WT1235–243-specific CD8
+ T cells by HLA-A*2402+ CD141+ DCs flow-purified from bone marrow of humanised mice after culture with
CLEC9A-WT1, DEC-205-WT1 or b-gal-WT1 (control). SFU, spot-forming unit (IFNc ELISPOT assay). Data are shown as mean + SD (four
humanised mice). *P = 0.0121, **P = 0.0073 (one-way ANOVA with Tukey’s test for multiple comparisons). (d) Priming of na€ıve WT1235–243-
specific CD8+ T cells after culture of unfractionated human CD45+ cells from humanised mouse spleens with CLEC9A-WT1, DEC-205-WT1 or b-
gal-WT1 (control). Data are shown as mean + SD (five humanised mice). SFU, spot-forming unit (IFNc ELISPOT assay). *P < 0.0001 (one-way
ANOVA with Tukey’s test for multiple comparisons). (e) Expansion of rat CD2+ WT1235–243-specific TCR
+ CD8+ T cells in humanised mouse
splenocytes 8 days after an initial 2 h prime with CLEC9A-WT1, DEC-205-WT1 or b-gal-WT1 (control) in the presence of activators poly I:
C + R848. Data are expressed as fold expansion normalised to expansion after culture with cognate peptide (dotted line). Each colour represents
cultures from the same humanised mouse. Horizontal bars show mean values (four humanised mice).
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in oncogenesis, making it an ideal
immunotherapeutic target in many cancer patients.
Efficient cross-presentation by CD141+ DCs after
uptake of CLEC9A-WT1 in vitro did not require
prior activation, consistent with our previous
work.47 However, adjuvants are known to
enhance T-cell priming induced by vaccines that
target DCs, at least in mouse models, and the
same may be true for CLEC9A-WT1. In this regard,
polyICLC is safe to administer in combination with
DEC-205-NY-ESO-1 and can effectively activate
CD141+ DCs, making this adjuvant a logical choice
to combine with CLEC9A-WT1.20,21,34 The route of
vaccine administration is yet to be addressed but
may not be optimal via the dermal route given
the reported lack of surface expression of CLEC9A
by dermal DC.55 Another consideration is that
systemic impairments in haematopoiesis in
advanced cancer patients can impact DC numbers,
although there is scant literature on the
functional and numerical integrity of CD141+ DCs
under these circumstances. MoDC-based vaccines
have shown the greatest clinical benefit in high-
risk AML patients with MRD.14 Although CD141+
DCs are depleted in patients with newly
diagnosed AML and in patients with relapse/
refractory AML, they recover in the setting of
MRD after chemotherapy or allogeneic stem cell
transplantation,56 suggesting that vaccination
with CLEC9A-WT1 will not only be feasible, but
will also likely be most efficacious in this setting
as an adjunctive treatment for AML. WT1 peptide,
protein and moDC-based vaccines have also been
administered safely to patients with MDS, chronic
myeloid leukaemia, non-Hodgkin’s lymphoma,
multiple myeloma, paediatric leukaemias and
advanced solid malignancies including breast,
lung, renal, ovarian, and pancreatic cancers, and
glioblastoma.7,10,57-63 CLEC9A-WT1 therapy may
therefore be suitable for patients with any of
these malignancies, and any defects in CD141+ DC
numbers could be overcome by the administration
of Flt3L.64 Mouse cDC1s play a key role in
responses to radiation therapy, viral therapies,
adoptive T-cell therapies and immune checkpoint
inhibitors.25,26,28-31,40,65,66 Accordingly, CLEC9A-
WT1 vaccines also hold the potential to enhance
immunogenicity and response rates when
combined with a variety of immunotherapies and
standard treatments in patients with cancers that
express WT1.
The generation of comparable CLEC9A-WT1 and
DEC-205-WT1 vaccines on the same IgG4
backbone in this study enabled a direct
comparison of two distinct specificities targeting
the same Ag to CD141+ DCs. Superior cross-
presentation of the HLA-A*0201-restricted and
HLA-A*2402-restricted WT1 epitopes was observed
with CLEC9A-WT1, despite equivalent or superior
binding of DEC-205-WT1 to CD141+ DCs. A similar
result was obtained previously with an
immunodominant HLA-A*0201-restricted pp65
epitope from CMV.47 This phenomenon may be
explained by the fact that DEC-205 trafficks to
lysosomes, whereas CLEC9A localises to early
endosomes, which favor cross-presentation.16,54,67
These data emphasise the choice of receptor as an
important consideration in vaccine design and
show that Ag delivery to the cross-presentation
pathway can enhance the immunogenicity of
specific formulations that target CD141+ DCs.
To compare the priming capabilities of CLEC9A-
WT1 and DEC-205-WT1, we generated humanised
mice reconstituted with human immune cell
subsets, including a small repertoire of na€ıve
WT1235–243-specific CD8
+ T cells. Using splenocytes
from these mice, we demonstrated that CLEC9A-
WT1 can induce CD141+ DC-mediated priming of
human na€ıve WT1-specific T cells, in contrast to
DEC-205-WT1. These data apparently conflict with
a previous study in which both anti-CLEC9A and
anti-DEC-205 Abs were able to prime murine CD8+
T cells by preferentially targeting cDC1s.46 Our
model nonetheless supports the notion that
effective CD8+ T-cell priming in humans can be
achieved by specific targeting of Ag to CD141+
DCs.
It is important to note that Ag-presenting cells
other than CD141+ DCs can prime CD8+ T cells, and
the extent to which this occurs in humans may not
have been fully revealed using the DEC-205-WT1
vaccine. For example, human CD1c+ DCs, which are
more abundant than CD141+ DCs and equivalent to
mouse cDC2s, do not efficiently cross-present Ags
after delivery via DEC-205.16,67 In contrast,
equivalent levels of cross-presentation were
observed in vitro with human CD1c+ DCs and human
CD141+ DCs after Ag delivery via CD40, which
trafficks to early endosomes, like CLEC9A.67,68 Anti-
DEC-205 and anti-CD40 Abs conjugated to influenza
matrix protein M1 epitopes nonetheless reactivated
M1-specific memory CD8+ T cells to a similar extent
in a humanised mouse model, suggesting that cross-
presentation by both CD1c+ DCs and CD141+ DCs is
unlikely to enhance CD8+ T-cell responses in vivo.68
In addition, both CD1c+ DCs and CD141+ DCs process
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and present epitopes to reactivate memory CD4+ T
cells after Ag delivery via DEC-205.47 Consequently,
Ag delivery to CD1c+ DCs may further enhance
tumor-specific CD4+ T-cell responses, even though
anti-CLEC9A and anti-DEC-205 Abs promote CD4+ T-
cell responses similarly after uptake by CD141+ DCs.69
Chimeric anti-CLEC9A and anti-DEC-205 Abs also
prime HIV-specific CD4+ T-cell responses to a similar
extent in mice.46 In mice and macaques, CLEC9A Ab
targeting also induces potent humoral responses,
even in the absence of adjuvant.70 Although this is
yet to be explored in humans, the potential for high
titre Ab responses could be a limitation to multiple
treatment cycles that may be required for enhanced
cellular immunity. Targeting a single known TAA is a
further potential limitation of this vaccine; however,
conjugation of other TAA individually or in
combination should also be feasible. Further work is
therefore required to assess the overall
immunogenicity and clinical efficacy of different
chimeric Abs, which collectively provide a generic
platform to develop novel vaccines against
numerous cancers and infectious agents.
Our data show that a CLEC9A-WT1 vaccine
selectively targets CD141+ DCs, leading to
enhanced cross-presentation and activation of
na€ıve and memory WT1-specific CD8+ T cells.
Collectively, these findings identify a promising
new vaccine candidate for malignancies that
express WT1.
METHODS
Blood samples
Peripheral venous blood was obtained from healthy adult
volunteers, and umbilical cord blood (UCB) was obtained
from the Queensland Cord Blood Bank. Written informed
consent was obtained for sample acquisition in line with
standards established by the Declaration of Helsinki. Study
approval was granted by the Mater Human Research Ethics
Committee (HREC13/MHS/83 and HREC13/MHS/86). CD34+
haematopoietic stem cells (HSCs) were isolated from UCB
using a CD34+ Isolation Kit (Miltenyi Biotec, Bergisch
Gladbach, North Rhine-Westphalia, Germany) and
cryopreserved at "80 °C. Typing for HLA-A*0201 and HLA-
A*2402 was confirmed by PCR.52,71
Generation and validation of human
CLEC9A-WT1 and DEC-205-WT1 vaccines
Expression constructs were generated in pcDNA3.1+
plasmids encoding the human IgG4 and j constant regions
and the variable regions of rat anti-human CLEC9A clone
4C6, mouse anti-human DEC-205 clone MMRI-7, or rat
anti-bacterial b-galactosidase (b-gal) clone GL117.47 The
antibody heavy chain sequence was fused to cDNA
encoding an alanine linker, the WT1 antigenic sequence
AAAASSGQARMFPNAPYLPSSQLECMTWNQMNLGACNKRYFKL
SHLQMHSRKHTGSGSGDYKDDDDK (corresponding to amino
acid positions 124-136, 231-245, 330-349 of WT1, isoform
CRA_a; Sequence ID: EAW68220.1), a serine-glycine linker,
and a FLAG tag to facilitate purification and detection of
the chimeric Ab (GeneArt Thermo Fisher Scientific,
Waltham, MA, USA). The resulting chimeric Abs, each
carrying two WT1 antigenic sequences, were expressed in
mycoplasma-free Freestyle 293F cells (Invitrogen Thermo
Fisher Scientific, Waltham, MA, USA) using 293fectin
(Invitrogen Thermo Fisher Scientific, Waltham, MA, USA)
and purified from the culture supernatant by affinity
chromatography using Protein A Sepharose (GE Healthcare,
Chicago, IL, USA). Ab specificity was confirmed by binding
to 293F cells transiently transfected with full-length
recombinant CLEC9A or DEC-205 and by binding to
recombinant CLEC9A, DEC-205 or b-gal recombinant
proteins by ELISA.47
To assess binding specificity to human peripheral blood
mononuclear cell (PBMC) subsets, PBMCs were isolated from
adult blood by density gradient centrifugation using Ficoll-
Paque (GE Healthcare), and a fraction of these cells were
enriched using an Easysep Human Myeloid DC Enrichment
Kit (Stemcell Technologies, Vancouver, BC, Canada). PBMCs
and enriched myeloid DCs were blocked with 10% mouse
serum and 10% rat serum (Sigma-Aldrich, Saint Louis, MO,
USA) and incubated with CLEC9A-WT1, DEC-205-WT1 or b-
gal-WT1 (control-WT1) vaccines (Monash University,
Clayton, VIC, Australia), followed by anti-human IgG4-biotin
(Invitrogen Thermo Fisher Scientific). PBMCs were then
stained with streptavidin-PE (SA-PE, Invitrogen Thermo
Fisher Scientific), Live/Dead (Zombie) Aqua (BioLegend, San
Diego, CA, USA), and anti-CD3-BV711 (clone OKT3), anti-
CD19-Pacific Blue (clone HIB19), anti-CD20-Pacific Blue
(clone 2H7), anti-CD56-FITC (clone HCD56), anti-CD14-APC
(clone HCD14), anti-CD16-BV785 (clone 3G8), anti-HLA-DR-
PerCP-Cy5.5 (clone L243), anti-CD11c-PE-CF594 (clone B-LY6,
BD Biosciences, San Jose, CA, USA) and anti-CD123-BUV395
(clone 7G3, BD Biosciences). Enriched myeloid DCs were
stained with SA-PE (Invitrogen Thermo Fisher Scientific),
Live/Dead Aqua (BioLegend), anti-CD141-PE-Cy7 (clone
M80), anti-CD1c-Alexa Fluor 700 (clone L161), anti-HLA-DR-
PerCP-Cy5.5 (clone L243), and the lineage-specific Abs anti-
CD3-Pacific Blue (clone OKT3), anti-CD14-Pacific Blue (clone
HCD14), anti-CD16-Pacific Blue (clone 3G8), anti-CD19-
Pacific Blue (clone HIB19), anti-CD20-Pacific Blue (clone 2H7)
and anti-CD56-Pacific Blue (clone HCD56). All Abs were
purchased from BioLegend unless stated otherwise. Data
were acquired using an LSRFortessa X-20 (BD Biosciences) or
a CytoFLEX-S flow cytometer (Beckman Coulter,
Indianapolis, IN, USA) and analysed using FlowJo software
version 9 or 10 (Tree Star, Inc., Ashland, OR, USA).
Expansion and differentiation of human
CD141+ DCs in vitro
CD34+ HSCs were expanded and differentiated into DCs
using a previously reported method with modifications.48
Briefly, CD34+ HSCs were expanded for 7 days in StemSpan
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medium (Stemcell Technologies) supplemented with 10%
fetal bovine serum (FBS, Gibco Thermo Fisher Scientific),
FMS-like tyrosine kinase 3 ligand (Flt3L, 100 ng mL"1), stem
cell factor (SCF, 100 ng mL"1), interleukin-3 (IL-3,
20 ng mL"1) and thrombopoietin (TPO, 50 ng mL"1) (all
from PeproTech, Rocky Hill, NJ, USA), together with
StemRegenin-1 (SR-1, 1 µM, Stemcell Technologies). HSCs
were then differentiated into DCs for 10–11 days in RPMI
1640 medium (Gibco Thermo Fisher Scientific)
supplemented with 10% FBS (Gibco Thermo Fisher
Scientific), HEPES (10 mM), sodium pyruvate (1 mM),
penicillin/streptomycin (100 U mL"1) and GlutaMAX (2 mM)
(all from Gibco Thermo Fisher Scientific), together with b-
mercaptoethanol (50 µM, Sigma-Aldrich), FLt3L
(100 ng mL"1, PeproTech), SCF (20 ng mL"1, PeproTech), IL-
4 (2.5 ng mL"1, Invitrogen Thermo Fisher Scientific), GM-CSF
(2.5 ng mL"1, Invitrogen Thermo Fisher Scientific) and
StemRegenin-1 (SR-1; 1 µM, Stemcell Technologies). DCs
were phenotyped by staining the cultures with Live/Dead
Aqua (BioLegend), lineage-specific Abs conjugated to
Pacific Blue (see above), and anti-HLA-DR-PE-Cy7 (clone
L243), anti-CD11c-PE-CF594 (clone B-ly6, BD Biosciences),
anti-CD141-BV711 (clone 1A4, BD Biosciences), anti-CADM1-
Alexa Fluor 647 (clone 3E1, MBL, Woburn, MA, USA) and
anti-CLEC9A-PE (clone 8F9). For binding assays, cells were
incubated with CLEC9A-WT1, DEC-205-WT1 or control-WT1
Abs, followed by anti-human IgG4-biotin (Invitrogen
Thermo Fisher Scientific), and then the DC phenotyping Ab
cocktail (see above) with SA-PE (Invitrogen Thermo Fisher
Scientific). Data were acquired using an LSRFortessa X-20
(BD Biosciences) and analysed using FlowJo software
version 9 or 10 (Tree Star Inc.). In some experiments,
CD141+ DCs were flow-purified from the cultures using a
MoFlo Astrios (Beckman Coulter) after staining with Live/
Dead Aqua (BioLegend), lineage-specific Abs conjugated to
Pacific Blue (see above), and anti-HLA-DR-PE-Cy7 (clone
L243), anti-CD11c-PE-CF594 (clone B-ly6, BD Biosciences) and
anti-CD141-APC (clone 1A4, BD Biosciences).
Humanised mice
All animal experiments were approved by the University of
Queensland Animal Ethics Committee and conducted in
accordance with the Australian Code for the Care and Use
of Animals for Scientific Purposes. NSG-A24 (NOD.Cg-
PrkdcscidIL2rgtm1Whl Tg (HLA-A24/H2-D/B2M) 3Dvs/Sz) mice
transgenic for human HLA-A*240252 were kindly provided
by Professor Leonard Shultz (The Jackson Laboratory, Bar
Harbor, ME, USA). Humanised NSG-A24 mice were
generated by irradiation (10 Gy) of 2- to 5-day-old neonates
followed by intrahepatic injection of human HLA-A*2402+
progenitor cells as described previously for NSG-A2 mice.49
Reconstitution of human CD45+ cells was confirmed at 10–
14 weeks, after which humanised mice received 2 9 50 µg
subcutaneous (s.c.) injections of Flt3L (Bio-X Cell, West
Lebanon, NH, USA) separated by an interval of 4 days.
CD141+ DCs were flow-purified from humanised mouse
bone marrow suspensions using a FACSAria Fusion Sorter
(BD Biosciences) after first depleting mouse CD45+ and
human CD3+, CD14+, CD19+, CD20+ and CD34+ cells by
magnetic separation (Dynabeads Magnetic Beads, Thermo
Fisher Scientific), and then staining with Live/Dead Aqua
(BioLegend), anti-CD45-APC-Cy7 (clone H130, lineage-
specific Abs conjugated to Pacific Blue (see above), and
anti-HLA-DR-PE-Cy7 (clone L243), anti-CD1c-PE (clone L161),
anti-CD123-PerCP-Cy5.5 (clone 6H6) and anti-CD141-APC
(clone 1A4, BD Biosciences) as described previously.49
T-cell lines, peptides, and tetramers
T-cell lines specific for the HLA-A*2402-restricted WT1235–245
epitope (CMTWNQMNL) were generated after transfer of a
WT1235–243-specific T-cell receptor (TCR)-encoding lentivirus
into primary UCB CD8+ T cells (Supplementary figure 3). T-
cell lines specific for the HLA-A*0201-restricted WT1126–134
epitope (RMFPNAPYL) were generated from healthy donors
by expansion of CD8+ T cells with WT1126–134 peptide-pulsed
moDCs, followed by enrichment using streptamer
technology, single cell FACs sorting and expansion of clones
as described previously.72 The corresponding peptides were
purchased from GL Biochem (Shanghai, China). WT1235–243/
HLA-A*2402 tetramers were generated as described
previously.73
Cross-presentation assays
Flow-purified HLA-A*2402+ or HLA-A*0201+ CD141+ DCs
generated from in vitro cultures or humanised mice were
incubated with 10 µg mL"1 CLEC9A-WT1, DEC-205-WT1, or
control-WT1 vaccines, or an equivalent amount of
recombinant WT1 protein (0.7 µg mL"1, Mimotopes,
Mulgrave, VIC, Australia) or no Ag, for 2 h at 37 °C in RPMI
1640 medium (Gibco Thermo Fisher Scientific)
supplemented with 10% FBS, HEPES (10 mM), sodium
pyruvate (1 mM), penicillin/streptomycin (100 U mL"1),
GlutaMAX (2 mM) and non-essential amino acids (0.1 mM)
(all from Gibco Thermo Fisher Scientific), together with 2-
mercaptoethanol (50 µM, Sigma-Aldrich). After washing, DCs
were incubated with WT1-specific T-cell lines for 16–20 h at
37 °C on ELISPOT plates (Merck Millipore, Darmstadt,
Germany) precoated with an anti-human IFN-c Ab (clone 1-
D1K, Mabtech, Nacka Strand, Sweden). Wells were
developed using anti-human IFN-c-biotin (clone 7-B6-1),
streptavidin–alkaline phosphatase and BCIP/NBT-plus
substrate (all from Mabtech). Spots were counted using an
AID ELISPOT reader (Autoimmun Diagnostika GmbH,
Strassberg, Germany) and ImmunoSpot CTL (Cellular
Technology Limited, Cleveland, OH, USA).
CD8+ T-cell priming assays
Human CD34+ HSCs were incubated overnight in X-VIVO 15
medium (Lonza, Basel, Switzerland) supplemented with
10% FBS (Gibco Thermo Fisher Scientific), Flt3L
(50 ng mL"1), SCF (50 ng mL"1), IL-3 (20 ng mL"1) and TPO
(50 ng mL"1) (all from PeproTech). Cells were then
transferred to plates precoated with RetroNectin
(20 µg mL"1, Clontech, Takara, Mountain View, CA, USA)
and blocked with human serum albumin (2%). A WT1235–
243-specific TCR-encoding lentivirus was added at a
multiplicity of infection of 100, and HSCs were incubated
for a further 24 h, washed and engrafted intrahepatically
into NSG-A24 mice. Reconstitution of human CD45+ cells
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was confirmed at 10–12 weeks, after which humanised mice
received 2 9 50 µg s.c. injections of Flt3L (Bio-X Cell)
separated by an interval of 4 days. Spleens from humanised
mice were digested in collagenase IV (Worthington
Biochemical, Lakewood, NJ, USA) and DNase I (Roche, Basel,
Switzerland), separated over a Percoll density gradient, and
enriched for human leucocytes using a Mouse/Human
Chimera EasySep Kit (Stemcell Technologies). Expression of
the WT1235–243-specific TCR was confirmed by staining with
the corresponding tetramer conjugated to APC, followed by
anti-mouse CD45-V500 (clone 30-F11, BD Biosciences), anti-
rat CD2-PE (clone OX-34), and the anti-human Abs anti-
CD45-BUV395 (clone HI30, BD Biosciences), anti-CD3-Pacific
Blue or anti-CD3-BV711 (clone OKT3), anti-CD8-PE-Cy7
(clone RPA-T8), anti-CD197-BV711 (clone 3D12, BD
Biosciences) and anti-CD45RA-BV786 (clone HI100, BD
Biosciences). Binding of CLEC9A-WT1 and DEC-205-WT1 to
humanised mouse splenocytes was confirmed by staining
with the chimeric Abs, followed by anti-human IgG4-biotin
(Invitrogen Thermo Fisher Scientific), and then SA-PE
(Invitrogen Thermo Fisher Scientific), Live/Dead Aqua
(BioLegend), anti-mouse CD45-V500 (clone 30-F11, BD
Biosciences), and the anti-human Abs anti-CD45-APC-Cy7
(clone H130), anti-CD3-BV711 (clone OKT3), anti-CD19-
Pacific Blue (clone HIB19), anti-CD20-Pacific Blue (clone
2H7), anti-HLA-DR-PerCP-Cy5.5 (clone L243), anti-CD11c-PE-
CF594 (clone B-ly6, BD Biosciences), anti-CD14-APC (clone
HCD14), anti-CD16-BV785 (clone 3G8), anti-CD56-FITC (clone
HCD56), anti-CD8-BUV395 (clone RPA-T8), anti-CD1c-Alexa
Fluor 700 (clone L161), anti-CD11b-BV650 (clone M1/70),
anti-CD123-BUV395 (clone 7G3, BD Biosciences) and anti-
CD141-PE-Cy7 (clone 1A4, BD Biosciences). Data were
acquired using an LSRFortessa X-20 (BD Biosciences) and
analysed using FlowJo software version 9 or 10 (Tree Star
Inc.).
For ex vivo ELISPOT assays, splenocytes enriched with
human CD45+ cells were incubated overnight with
10 µg mL"1 CLEC9A-WT1, DEC-205-WT1 or control-WT1
vaccines. For CD8+ T-cell priming assays, splenocytes
enriched with human CD45+ cells were cultured with the
same chimeric Abs, WT1235–243 peptide or no Ag in the
presence of polyIC and R848 (InvivoGen, San Diego, CA,
USA) for 2 h at 37 °C, washed and then cultured for 9–
10 days in RPMI 1640 medium (Gibco Thermo Fisher
Scientific) supplemented with IL-2 (100 U mL"1, Invitrogen
Thermo Fisher Scientific), IL-7 (10 ng mL"1, Invitrogen
Thermo Fisher Scientific) and IL-15 (20 ng mL"1, PeproTech).
Expansion of WT1235–243-specific CD8
+ T cells was analysed
by staining with the corresponding tetramer conjugated to
APC, followed by anti-rat CD2-PE (clone OX-34) and the
anti-human Abs anti-CD45-BUV395 (clone HI30, BD
Biosciences), anti-CD3-Pacific Blue or anti-CD3-BV711 (clone
OKT3), and anti-CD8-PE-Cy7 (clone RPA-T8).
Statistical analysis
Data were tested for normality using the Kolmogorov–
Smirnoff test. Multigroup comparisons were performed
using a repeated measures one-way ANOVA or the non-
parametric equivalent (Friedman test), followed by the
appropriate post-test (Tukey or Dunn). Paired comparisons
were performed using a paired t-test or the non-parametric
Wilcoxon’s signed rank test. Statistical significance was
defined as a P value ≤ 0.05. All tests were performed using
Prism version 5 (GraphPad, San Diego, CA, USA).
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